Biogen Inc.

Biogen Inc. Earnings Recaps

BIIB Health Care 2 recaps
Q1 2026 Apr 30, 2026

Biogen shares rose 3.2% following first-quarter results, as investors welcomed the 12% growth in the company's key growth products and positive updates on both the LEQEMBI program and the high-dose SPINRAZA launch. The market reaction suggests upside surprise relative to expectations, with attention on stabilization after years of decline and a promising integration roadmap for the pending Apellis acquisition.

Key takeaways
  • Growth products delivered $850 million in revenue for Q1, up 12% year-over-year, offsetting continued declines from legacy MS and SPINRAZA.
  • High-dose SPINRAZA gained approvals in the U.S., Japan, and Europe; early patient feedback is positive, with reports of switchbacks due to enhanced efficacy profile.
  • The LEQEMBI franchise is progressing, with expanded maintenance use and a May 24 PDUFA date for the subcutaneous induction regimen, supporting easier patient access.
  • Management emphasized the expected accretion from the pending Apellis acquisition by 2027, expanding Biogen’s commercial portfolio in both ophthalmology and nephrology.
  • Cost discipline remains a focus, with a shift in commercial investment away from MS toward growth brands; management notes stabilization after multiple years of revenue and profit declines.
Full recap
Q3 2025 Oct 31, 2025

Biogen reported a robust third quarter in 2025, highlighted by a 67% growth in launch product revenues and strong demand for LEQEMBI and ZURZUVAE, positioning the company favorably within the neurological and autoimmune markets.

Key takeaways
  • Launch products drove significant revenue growth, with LEQEMBI sales reaching $121 million.
  • ZURZUVAE experienced a remarkable 150% increase in year-over-year revenue, reshaping perceptions of postpartum depression.
  • Biogen is advancing a strong pipeline, with 10 Phase III programs, including promising candidates for lupus and other autoimmune diseases.
  • The acquisition of Alcyone Therapeutics enhances Biogen's capabilities in delivering innovative therapies via ASO administration.
  • Strong talent acquisition indicates confidence in Biogen's commercial prospects and new product pipeline.
Full recap